Deepak Nitrite Limited Overview
Deepak Nitrite is one of India's largest chemical-intermediates groups, headquartered in Vadodara and controlled by the Mehta family. It operates through two reporting segments: Advanced Intermediates (AI), a legacy portfolio of nitrites, nitro-aromatics, xylidines, cumidines, oximes, fuel additives and optical brighteners sold to agrochemical, dyes/pigments, pharma, rubber and paper customers in India and 50+ export markets; and Phenolics, run through wholly owned subsidiary Deepak Phenolics, which makes phenol, acetone and isopropyl alcohol (IPA) at Dahej and holds roughly half of the Indian phenol/acetone market. Phenolics now generates about two-thirds of revenue and the large majority of segment profit. The group is in the middle of its largest-ever investment cycle — an approximately INR 11,500 Cr propylene-to-polycarbonate chain via Deepak Chem Tech, plus a newly approved INR 2,500 Cr bisphenol-A plant — repositioning it from an intermediates maker toward an integrated import-substitution platform in phenol derivatives and engineering polymers.
What the company does
Deepak Nitrite manufactures and sells chemical intermediates — molecules that customers transform into finished products such as crop-protection active ingredients, dyes and pigments, rubber chemicals, pharmaceuticals, paper brighteners, solvents, resins and plastics. The company does not sell to consumers; it is a business-to-business supplier positioned upstream and midstream in the chemical value chain.
Company's own description (paraphrased from the FY2026 results presentation): DNL characterizes itself as one of India's fastest-growing and most trusted chemical-intermediates companies, with a diversified product portfolio serving multiple industries and applications. It emphasizes recognition by global customers as a responsible manufacturer and preferred supplier, highlights its process expertise and operational excellence, and states that it has 7 modern manufacturing facilities, exports to 50+ countries across 6 continents, and is India's largest producer of phenol, acetone, IPA and sodium nitrite. The presentation cites 36+ products, 56+ applications, FY2026 total revenue of INR 7,947 Cr and a workforce of 6,100+.
Independent characterization: In economic substance, DNL is two businesses under one roof:
-
A cumene-based phenol/acetone/IPA producer (Deepak Phenolics, Dahej) whose earnings are driven by the spread between benzene/propylene feedstock costs and phenol/acetone/IPA realizations — a cyclical, petrochemical-style commodity business, but one with a structural moat as the dominant domestic producer in an import-dependent market, with India-landed import parity pricing and logistics advantages.
-
A specialty/fine-chemical intermediates business (Advanced Intermediates, standalone DNL) with leading positions in niche molecules (sodium nitrite, nitro-toluenes, xylidines, cumidines, oximes, fuel additives, DASDA/OBA). This business is more specialty in nature but has been under severe pressure since FY2024 from Chinese oversupply and dumping, with EBIT margins collapsing from ~16% (FY24) to ~3–8% in recent quarters.
Overlaying these is a third, emerging business — advanced materials (polycarbonate compounding via Deepak Advanced Materials, and the forthcoming polycarbonate resin and BPA plants via Deepak Chem Tech) — which is pre-revenue at scale but will dominate capital allocation through FY2029.
Business and revenue model
| Dimension | Characterization |
|---|---|
| Revenue type | ~100% product sales (manufactured chemicals). No material service, subscription or licensing revenue. |
| Pricing | Largely spot/contract pricing linked to international benchmarks and import parity (Phenolics); negotiated contract pricing with key accounts, often with raw-material pass-through mechanisms (AI). |
| Customer types | Agrochemical formulators/AI makers, dye & pigment makers, pharma API makers, rubber chemical makers, paper & detergent makers (OBA), laminates/resin makers (phenol), solvent/pharma users (acetone, IPA), and future polymer converters (PC). |
| Geographic mix | ~85% domestic / ~15% export (Q1 FY27 consolidated). AI is ~50:50 domestic/export; Phenolics is almost entirely domestic (management, Q1 FY27 call). |
| Value-chain position | Upstream-to-midstream. Backward integration is a strategic priority: in-house nitric acid (commissioned December 2025), propylene and hydrogen via a 15-year Petronet LNG pipeline agreement, HyCO via Praxair (Linde). Forward integration into MIBK/MIBC, acetophenone, BPA and polycarbonate. |
| End-markets | Agrochemicals, colorants (dyes & pigments), pharmaceuticals, rubber, plastics & laminates, paper, textiles, home & personal care, paints & coatings, construction chemicals, automotive/electronics (via PC), energy (fuel additives). |
Legal-entity structure (group)
| Entity | Ownership | Role | Source |
|---|---|---|---|
| Deepak Nitrite Limited (DNL) | Listed parent | Advanced Intermediates manufacturing (Nandesari, Roha, Taloja, Hyderabad and other sites) | Company filings |
| Deepak Phenolics Limited (DPL) | 100% | Phenol, acetone, IPA at Dahej; existing capacity 330 KTA phenol, 200 KTA acetone, 80 KTA IPA | Company press releases (Apr 2025) |
| Deepak Chem Tech Limited (DCTL) | 100% (equity); preference capital held by DNL and DPL | Growth-project vehicle: nitric acid, fluorination, MIBK/MIBC, acetophenone, chlorination, new phenol/acetone/IPA, BPA and polycarbonate; incorporated 9 October 2020 | Moneycontrol, ScanX, company filings |
| Deepak Advanced Materials Limited (DAML) | 100% | Polycarbonate and engineering-polymer compounding at Manjusar, Savli (Vadodara) | Company press release |
| Deepak Nitrite Corporation Inc. (USA) | 100% | Overseas trading/marketing subsidiary | ICRA rationale (Aug 2025) |
| Oman entity ("DN Oman") | Referenced by ICICI Securities (Apr 2025) as a project in commissioning | — | — |
Strategy
Stated strategic themes (paraphrased from FY2026 presentation, calls and press releases)
-
Integration as resilience. Build backward integration (nitric acid, propylene/hydrogen via pipeline, HyCO) and forward integration (MIBK/MIBC, acetophenone, BPA, PC) so that margins are less exposed to traded-intermediate volatility. The CMD has stated that once the integrated projects are complete, Deepak will be among the world's largest single-site phenol/acetone producers, with over half of capacity converted into derivatives such as BPA and PC resins.
-
Import substitution / "Make in India." Target molecules where India is structurally import-dependent (phenol, acetone, MIBK, BPA, polycarbonate), aligned with Atmanirbhar Bharat and leveraging Dahej PCPIR infrastructure.
-
Responsible Chemistry. Transition toward 60–70% renewable energy, green chemistry, effluent recycling (MVR, ASP/MBR), and circularity.
-
From intermediates supplier to "fit-for-effect" partner. Move up the value chain toward formulated compounds and engineering polymers for marquee end-customers.
-
Domestic-first growth. Lean on resilient Indian demand while export markets face Chinese oversupply.
Strategic initiatives register (last ~24 months)
| Date | Initiative | Investment | Status |
|---|---|---|---|
| Nov 2024 | Polycarbonate resin project (165 KTA, Dahej) with Trinseo licence and asset purchase | ~INR 5,000 Cr initially; now part of ~INR 11,500 Cr integrated propylene-to-PC programme | ~INR 1,200 Cr spent by Q1 FY27; commissioning H2 FY28–FY29 |
| c. Mar 2025 | PC compounding (DAML) | — | Operating |
| Apr 2025 | New phenol (300 KTA), acetone (185 KTA), IPA (100 KTA) complex (DCTL) | ~INR 3,500 Cr | Under execution; timed to Petronet's propane dehydrogenation propylene supply |
| 2024–25 | 15-year Petronet LNG propylene (250 KTPA) and hydrogen (11 KTPA) supply | — | Contracted |
| Oct 2025 | DRDC 2.0 R&D centre | — | Operating |
| Dec 2025 | Nitric acid plant (DCTL, Nandesari) | ~INR 515 Cr | Operating |
| May 2026 | HyCO plant agreement with Praxair India (Linde) | Third-party build-own-operate (terms undisclosed) | Targeted 2028 |
| Apr–Aug 2026 | Leadership restructuring (Deputy MDs, CEO-AI, ED & CMO, new independents) | — | Effective |
| Aug 2026 | MIBK/MIBC and acetophenone (DCTL, Dahej) | ~INR 735 Cr | Commissioned 6 Aug 2026 |
| Aug 2026 | BPA plant 240 KTA (DCTL) | ~INR 2,500 Cr | Approved 4 Aug 2026 |
| Q2 FY27 | Multipurpose agrochemical intermediates facility | — | Guided for commissioning in Q2 FY27 |
| Sep 2026 | Chlorination & specialty chemical plant (DCTL, Dahej) | ~INR 300 Cr | Commissioned 29 Sep 2026 |
| Ongoing | Renewable energy investments | — | ~INR 4.5 Cr savings in Q1 FY27; ~INR 20 Cr annualized expected |
Medium-term targets and guidance
| Item | Guidance | Source |
|---|---|---|
| Capex FY2026 | ~INR 1,200–1,300 Cr | Q3 FY26 commentary (TradeBrains) |
| Capex FY2027 | ~INR 2,500 Cr | Same |
| PC programme funding | ~60:40 debt:equity; debt tied up | Q1 FY27 call |
| Peak group debt | INR 8,000–8,500 Cr incl. working capital; D/E < 1x | Management, reported Sep 2026 |
| Propylene-based run rate | ~100 KT annualized currently; debottlenecking toward ~400 KT short-to-medium term (as reported by ZoomInfo summary; interpret with caution) | Q1 FY27 call summary |
| PC/BPA commissioning | PC H2 FY2028–FY2029; BPA a couple of months after | Q1 FY27 call |
| Explicit revenue/margin targets | — | — |
Products & Services
DNL does not publish list prices; pricing is contract- or spot-based and not disclosed. Launch years are given where known.
Advanced Intermediates
| Product / line | Description & applications | Target customers | Position / notes |
|---|---|---|---|
| Sodium nitrite | Inorganic intermediate for dyes, pharma, rubber chemicals, meat curing, heat-transfer salts, corrosion inhibition | Dye makers, pharma, rubber chemicals, metal treatment | India's largest producer; aggregator cites ~75% domestic share across sodium nitrite/nitrate/nitro-toluenes. Original 1972 product |
| Sodium nitrate | Explosives, glass, fertilizer and heat-transfer applications | Industrial users | Co-product with sodium nitrite |
| Nitro-toluenes (ONT, PNT, MNT) | Nitration of toluene; precursors for toluidines, dyes, agrochemicals | Dye and agro intermediates makers | Market leader in India |
| Nitro-toluidines | Downstream amines for pigments and agro AIs | Pigment and agro makers | — |
| Xylidines | Aromatic amines for agrochemicals (e.g., herbicides/fungicides) and pharma | Global agrochemical majors | Ranked among top 3 global producers |
| Cumidines | Amines for herbicides and specialty uses | Agrochemical makers | Among top 3 globally |
| Oximes | Anti-skinning agents in paints; agro intermediates | Paint and agro customers | Among top 3 globally |
| Fuel additives | Cetane improvers and related additives (e.g., nitrate-based) | Refiners, fuel marketers | Market leader domestically (ICRA) |
| Specialty agrochemical intermediates | Multi-step intermediates; new multipurpose agro-intermediates facility commissioned in Q2 FY27 (management guidance) | Agro innovators and generics | Under pricing pressure from China |
| Optical Brightening Agents (OBA) | Fluorescent whitening agents for paper, detergents, textiles; a new OBA variant introduced in FY2025 | Paper mills, detergent makers | Part of former Performance Products |
| DASDA (diamino stilbene disulfonic acid) | Key intermediate for OBAs | OBA makers | Acquired 2006 (Vasant Chemicals); Hyderabad |
| Benzotrifluoride and fluorinated intermediates | Fluorination chemistry for agro/pharma | Agro and pharma makers | DCTL's first fluorination plant at Dahej (~INR 220 Cr fluorochemicals capex referenced) |
| Nitric acid (weak and concentrated) | Captive feedstock for nitration; enables supply security | Captive (DNL standalone) | ~INR 515 Cr plant, Nandesari; operations began December 2025; designed to meet DNL's full requirement (~70 KTPA referenced by ICICI Securities) |
| Chlorination & specialty chemicals | New chlorination-based derivatives | Agro, pharma | ~INR 300 Cr DCTL plant, Dahej; commissioned 29 September 2026 |
| Hydrogenation / photo-chlorination products | Amine and chlorinated derivatives | Agro, pharma, dyes | Projects referenced by HDFC Securities (Jan 2025); status of each not individually verified |
Phenolics
| Product | Capacity | Applications | Position |
|---|---|---|---|
| Phenol | 330 KTA (DPL, Dahej); +300 KTA approved at DCTL | Phenolic resins, laminates, BPA, alkyl phenols, agro, pharma | ~50% domestic market share; company calls its plant one of the lowest thermal-footprint phenol plants globally (company claim) |
| Acetone | 200 KTA (DPL); +185 KTA approved | Solvents, pharma, MIBK/MIBC, BPA | Largest Indian producer |
| Isopropyl alcohol (IPA) | 80 KTA (DPL); +100 KTA approved | Pharma solvent, sanitizers, coatings | Commissioned 2020; pharma-grade |
| MIBK (methyl isobutyl ketone) | Not disclosed (~INR 735 Cr MIBK/MIBC plant) | Solvent for paints, rubber antioxidant precursor | Commissioned 6 August 2026 (DCTL) |
| MIBC (methyl isobutyl carbinol) | — | Mining flotation frother, solvents | Commissioned August 2026; pre-commissioning runs reportedly exceeded design capacity |
| Acetophenone | — | Fragrances, resins, pharma | Commissioned August 2026; recovered from phenol process residues (industry-first claim) |
Advanced Materials (emerging)
| Product / project | Description | Status |
|---|---|---|
| Polycarbonate compounds | Customizable PC granules and engineering-polymer compounds in multiple grades and colours for automotive/e-mobility, electronics, construction, appliances, medical, aerospace | DAML plant, Manjusar/Savli; inaugurated c. March 2025 |
| Polycarbonate resin | 165 KTA plant at Dahej using Trinseo interfacial polymerization technology and relocated Stade (Germany) equipment; access to CALIBRE resin brand | Under construction; commissioning targeted H2 FY2028–FY2029 (originally Q4 FY2028) |
| Bisphenol A (BPA) | 240 KTA greenfield plant; captive feed to PC plus merchant sales to epoxy resin makers | Approved 4 August 2026 (~INR 2,500 Cr); commissioning a few months after PC |
Financial Narrative
Income statement (consolidated, INR Cr)
Sources: company press releases and presentations (FY22, FY23, FY24, FY25, FY26); operating profit excl. other income from Screener; FY22–FY23 EPS derived (PAT ÷ 13.64 Cr shares).
Gross profit: Not separately reported by DNL (Indian GAAP format). StockAnalysis reports TTM (June 2026) gross profit of INR 2,234 Cr.
Margins
Derived from 6.1.
Growth
Note on FY2021 PAT: Business Standard reported INR 775.81 Cr; Screener-derived series implies ~INR 757 Cr. Discrepancy likely reflects minority/OCI treatment.
Quarterly trajectory (consolidated, INR Cr)
Sources: company releases; Screener for EPS; Q1 FY26 EBITDA derived from Q1 FY27 +159% YoY.
Sources: Net worth FY22 from company press release; total assets from Moneycontrol; borrowings from TradeBrains (FY24 INR 286 Cr; FY26 INR 1,638 Cr); net cash/debt from StockAnalysis. Conflicts: MarketsMojo reports total debt of INR 1,025.71 Cr at March 2026 (vs INR 1,638 Cr); Tijori reports net debt of INR 990 Cr (Mar-26) and INR 358 Cr (Mar-25) vs StockAnalysis INR 1,176 Cr and INR 355 Cr; Simply Wall St reported March 2024 debt of INR 217 Cr with INR 585 Cr cash. Goodwill is believed immaterial (no large acquisitions), but the PC technology licence and Trinseo assets will add intangibles/CWIP.
Cash flow (INR Cr)
Sources: StockAnalysis (aggregator). Dividends paid approximated as INR 7.5 × 13.64 Cr shares for the prior year's final dividend. No buybacks have been announced.
Ratios
Additional data points (various dates, aggregator-sourced): ROE ~12.8% average over the last three years (Screener); TTM ROIC 11.5% (StockAnalysis); five-year average ROCE ~29% and ROE ~21% (MarketsMojo); management cited ROCE of ~15% in Q3 FY26 commentary (TradeBrains). Net debt/EBITDA FY2026 ≈ 1.1x (INR 1,176 Cr ÷ INR 1,041 Cr; derived). Asset turnover FY2025 ≈ 1.07x (INR 8,282 Cr ÷ INR 7,717 Cr; derived).
Commentary on trends, inflections and drivers
FY2022 — cyclical peak. Revenue grew 56% and EBITDA reached INR 1,646 Cr (24% margin) as phenol, acetone and IPA realizations stayed elevated after COVID-era supply disruptions and the phenol plant ran at high utilization. PAT of INR 1,067 Cr remains the group's high-water mark, and the balance sheet was net-cash.
FY2023–FY2025 — margin normalization and AI erosion. Revenue held around INR 7,700–8,300 Cr but EBITDA fell each year, from INR 1,337 Cr to INR 1,176 Cr. Two separate forces were at work: (i) phenolic spreads normalized from abnormal FY2022 levels, with Phenolics EBIT margins stabilizing around 13%; and (ii) the AI segment was hit by Chinese dumping, destocking in agrochemicals and weak European demand, sending its EBIT from INR 446 Cr (FY24, incl. insurance) to INR 176 Cr (FY25). Phenolics volume growth (+16% revenue in FY25) partly offset this.
FY2026 — trough. Revenue fell 5% to INR 7,887 Cr and PAT 21% to INR 551 Cr. Management attributed the weakness to crude-linked supply-chain disruption, pricing pressure and geopolitical uncertainty. Q2 and Q3 FY26 were the low points (EBITDA margins ~11%), before Q4 recovered to 18%.
Q1 FY2027 — sharp inflection. EBITDA of INR 554 Cr (21% margin) and PAT of INR 345 Cr were all-time quarterly records. Drivers cited: strong domestic phenol/acetone demand and realizations, proactive feedstock sourcing during volatile propylene markets, debottlenecked phenol volumes, renewable-energy savings (~INR 4.5 Cr in the quarter), and nitric-acid backward integration in AI. Management noted propylene supply constraints and a short maintenance shutdown limited throughput during the quarter.
Cash flow and leverage — structural shift. FCF turned negative in FY2025 and FY2026 as capex rose to INR 1,100–1,200 Cr a year, moving the group from net cash (FY24) to net debt (~INR 1,000–1,200 Cr at FY26). Management guides peak debt of INR 8,000–8,500 Cr including working capital, with debt/equity kept below 1x, and has said FY2027 capex will be roughly INR 2,500 Cr. Interest costs are rising (INR 23 Cr in Q1 FY27 vs INR 8 Cr in Q1 FY26), though much interest on projects is capitalized during construction — Screener flags possible interest capitalization. The cash conversion cycle has lengthened from 67 to 92 days over FY2022–FY2026, a working-capital watch point.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key products | Principal entity |
|---|---|---|---|
Advanced Intermediates (AI) | Legacy DNL businesses formerly reported as Basic Chemicals, Fine & Speciality Chemicals and Performance Products | Sodium nitrite, sodium nitrate, nitro-toluenes, nitro-toluidines, xylidines, cumidines, oximes, fuel additives, specialty agrochemical intermediates, optical brightening agents (OBA), DASDA, benzotrifluoride; plus new DCTL products (nitric acid, fluorination/chlorination/hydrogenation derivatives) | DNL standalone; DCTL |
Phenolics | Cumene-based phenol chain | Phenol, acetone, isopropyl alcohol (IPA); from August 2026 MIBK, MIBC, acetophenone (reporting allocation to be confirmed in Q2 FY27) | Deepak Phenolics; DCTL |
Revenue by Segment
| Segment (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Advanced Intermediates revenue (INR Cr) | 2,511 | 3,034 | 2,724 | 2,527 | 2,553 |
Phenolics revenue (INR Cr) | 4,303 | 4,971 | 5,003 | 5,805 | 5,401 |
Inter-segment elimination (INR Cr) | -12 | -32 | -46 | -50 | -67 |
Consolidated revenue from operations (INR Cr) | 6,802 | 7,972 | 7,682 | 8,282 | 7,887 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment EBIT (INR Cr)
| Segment EBIT (INR Cr) | FY2024 | FY2025 |
|---|---|---|
Advanced Intermediates EBIT (INR Cr) | 446 | 176 |
Phenolics EBIT (INR Cr) | 644 | 783 |
AI EBIT margin (%) | 16 | 7 |
Phenolics EBIT margin (%) | 13 | 13 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
AI revenue growth YoY (%) | -10 | -7 | 1 |
Phenolics revenue growth YoY (%) | 1 | 16 | -7 |
AI share of gross segment revenue (%) | 35 | 30 | 32 |
Phenolics share of gross segment revenue (%) | 65 | 70 | 68 |
Segment Overview — Advanced Intermediates
| Segment | Revenue (INR Cr) | YoY | QoQ | EBIT (INR Cr) | EBIT margin |
|---|---|---|---|---|---|
Advanced Intermediates | 803.85 | +33% | +14% | 66.98 | 8% |
Phenolics | 1,775.05 | +36% | +24% | 417.76 | 24% (vs 9% in Q1 FY26) |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 6,802 | 7,972 | 7,682 | 8,282 | 7,887 |
Total income incl. other income (INR Cr) | 6,845 | 8,020 | 7,758 | 8,366 | 7,947 |
EBITDA as reported by company (INR Cr) | 1,646 | 1,337 | 1,199 | 1,176 | 1,041 |
Operating profit excl. other income (INR Cr) | 1,607 | 1,292 | 1,127 | 1,095 | 987 |
Profit before tax (INR Cr) | 1,434 | 1,146 | 1,102 | 953 | 757 |
Net profit / PAT (INR Cr) | 1,067 | 852 | 811 | 697 | 551 |
EPS basic & diluted (INR) | 78.2 | 62.5 | 59.45 | 51.12 | 40.36 |
Dividend per share (INR) | — | — | — | 7.5 | 7.5 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin on total income (%) | 24.0 | 16.7 | 15.5 | 14.1 | 13.1 |
Operating margin excl. other income (%) | 23.6 | 16.2 | 14.7 | 13.2 | 12.5 |
PBT margin (%) | 21.1 | 14.4 | 14.3 | 11.5 | 9.6 |
Net margin on revenue (%) | 15.7 | 10.7 | 10.6 | 8.4 | 7.0 |
Valuation Snapshot
| Metric | Value |
|---|---|
Revenue CAGR FY2021–FY2026 (INR 4,360 Cr → 7,887 Cr) | ~12.6% |
Revenue CAGR FY2022–FY2026 | ~3.8% |
PAT CAGR FY2021–FY2026 (INR 776 Cr → 551 Cr) | ~−6.6% |
TTM (to June 2026) revenue | INR 8,575 Cr (+7.1% YoY) |
TTM PAT | INR 783 Cr |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 1,890 | 1,902 | 1,975 | 2,120 | 2,578 |
Total income (INR Cr) | 1,914 | — | 1,983 | 2,127 | 2,592 |
EBITDA (INR Cr) | 214 | — | 219 | 383 | 554 |
PAT (INR Cr) | 112 | 119 | 100 | 220 | 345 |
EPS (INR) | 8.23 | 8.70 | 7.32 | 16.11 | 25.30 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | — | — | 6,096 | 7,717 | — |
Net worth / equity (INR Cr) | 3,338 | — | — | — | — |
Total borrowings (INR Cr) | — | — | 286 | — | 1,638 |
Net cash (+) / net debt (−) (INR Cr) | 162 | 342 | 297 | -355 | -1,176 |
Equity share capital (INR Cr) | 27 | 27 | 27 | 27 | 27 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 824 | 650 | 874 | 625 | 539 |
Capital expenditure (INR Cr) | 187 | 358 | 738 | 1,122 | 1,185 |
Free cash flow (INR Cr) | 637 | 292 | 136 | -497 | -646 |
Dividends paid (INR Cr, approx.) | — | — | — | 102 | 102 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Working Capital (Days) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash conversion cycle (days) | 67 | 76 | 77 | 82 | 92 |
Debt/equity (x) | — | — | — | 0.22 | 0.28 |
Interest coverage TTM Jun-26 (x) | — | — | — | — | 18.3 |
Revenue by Region and Revenue by Region (%)
| Region (INR Cr) | FY2024 | FY2026 |
|---|---|---|
India domestic revenue (INR Cr) | 6,135 | 6,791 |
Export revenue (INR Cr) | 1,547 | 1,156 |
Domestic share (%) | 80 | 85 |
Export share (%) | 20 | 15 |
Segment Overview (2)
| Segment | Domestic | Export |
|---|---|---|
Advanced Intermediates | ~50% | ~50% |
Phenolics | ~100% | Negligible |
Valuation Snapshot — Price
| Metric | Value | Source |
|---|---|---|
Price (NSE) | INR 1,492.80 | Multiple |
52-week high / low | INR 1,897.90 / INR 1,280.00 (one source cites high of INR 1,904.4) | Dhan, IIFL, Investing.com |
1-month return | −15.3% | Dhan |
3-month return | −3.5% | Dhan |
1-year return | −18.65% | Dhan / ICICI Direct |
3-year return | −29.6% | Dhan |
5-year return | −38.0% | Dhan |
50 / 200 DMA | ~INR 1,647–1,679 / ~INR 1,633–1,683 | 5paisa, Dhan |
Index membership | Nifty Midcap 150 (per 2025 Moneycontrol report) | Moneycontrol |
Market Valuation
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Year-end market cap (INR Bn) | 339.6 | 270.8 | 338.6 | 340.1 | 234.2 |
Valuation Multiples
| Multiple | Deepak Nitrite | Notes |
|---|---|---|
P/E (TTM, on INR 783 Cr TTM PAT) | ~26x | Several sites still display ~88–98x using stale standalone EPS — ignore |
EV/EBITDA (TTM) | ~16.1x | StockAnalysis |
EV/Sales (TTM) | ~2.5x | StockAnalysis |
P/B | ~3.3–3.6x (conflicting sites show 6.3–7.5x using standalone book) | 5paisa, Dhan |
Dividend yield | ~0.5% | Multiple |
Analyst Ratings & Targets
| Broker | Date | Rating | Target | Basis |
|---|---|---|---|---|
ICICI Securities | 15 Apr 2025 | ADD | INR 2,120 | 30x FY27E P/E |
JM Financial | 29 May 2025 | Not captured | Not captured | Forecast FY27E EBITDA INR 1,705 Cr, FY28E INR 1,959 Cr |
HDFC Securities | Feb 2025 | Company update | Not captured | PC entry thesis |
MarketScreener consensus | Various | Historically "Outperform" | — | — |
Per-Share Data
| Metric | FY2021 | FY2025 | FY2026 |
|---|---|---|---|
Dividend per share (INR) | 5.5 | 7.5 | 7.5 |
Group Entities
| Entity | Agency | Rating | Outlook | Date |
|---|---|---|---|---|
Deepak Nitrite Ltd | ICRA | [ICRA]AA / [ICRA]A1+ (INR 490 Cr bank lines; earlier also INR 200 Cr CP) | Stable (from Positive) | Aug 2025 |
Deepak Nitrite Ltd | CRISIL | CRISIL AA / A1+ (INR 750 Cr) | Stable | — |
Deepak Phenolics Ltd | ICRA | AA / A1+ | — | Mar 2024 |
Deepak Chem Tech Ltd | ICRA | A / A2+ | Positive (Mar 2024) | — |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance (latest)
-
Commission the remaining Q2 FY27 projects (multipurpose agro-intermediates facility) after MIBK/MIBC/acetophenone (Aug 2026) and chlorination (Sep 2026).
-
Debottleneck phenol and align new phenol capacity with Petronet's propylene supply.
-
PC commissioning H2 FY2028–FY2029; BPA a few months later; total PC programme ~INR 11,500 Cr funded ~60:40 debt:equity.
-
FY2027 capex ~INR 2,500 Cr; peak debt INR 8,000–8,500 Cr; D/E below 1x.
-
No explicit revenue or EBITDA guidance.
Consensus growth expectations
Earlier broker models (JM Financial, May 2025) projected EBITDA growth to ~INR 1,705 Cr in FY2027 and ~INR 1,959 Cr in FY2028. Annualizing Q1 FY27 EBITDA (INR 554 Cr) gives ~INR 2,200 Cr, but this should not be treated as guidance given spread volatility.
Bull case
-
Phenolics operating leverage is real and repeatable: Q1 FY27 Phenolics EBIT of INR 418 Cr (24% margin) on INR 1,775 Cr revenue shows what full utilization plus integration yields; phenol capacity doubling adds volume on the same platform.
-
New derivatives broaden the earnings base: MIBK/MIBC, acetophenone, chlorination and the multipurpose agro plant come online in FY2027, adding value to captive acetone and diversifying AI.
-
Valuation already discounts a lot: at ~26x TTM P/E and ~16x EV/EBITDA with the stock 38% below its five-year level, a sustained recovery to ~INR 1,800–2,000 Cr EBITDA plus a credible PC narrative could re-rate the shares.
Bear case
-
Q1 FY27 may be a spread spike, not a new base: Phenolics EBIT margin swung from 9% to 24% within a year; FY2026 full-year PAT was only INR 551 Cr.
-
Capex dwarfs current earnings power: ~INR 11,500 Cr PC programme plus ~INR 2,500 Cr BPA versus FY26 OCF of INR 539 Cr; FCF negative for two years; peak debt of INR 8,000–8,500 Cr arrives before PC earnings.
-
AI segment may not recover: export revenue down 25% in two years and Q3 FY26 AI margin near 2%; Chinese overcapacity is structural, and global PC/BPA oversupply could hit returns on the new assets.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q2 FY27 results — sustainability of 20%+ EBITDA margin | ~Nov 2026 |
| Ramp-up utilization of MIBK/MIBC/acetophenone and chlorination plants | Q3–Q4 FY27 |
| Phenol/acetone spread trajectory and propylene availability | Ongoing |
| AI segment EBIT margin trend (target: return to double digits) | Each quarter |
| PC project milestones (Stade equipment relocation, civil works, licensor sign-offs) | Through FY2027 |
| BPA/phenol technology licensor announcements | Unconfirmed timing |
| Net debt build and any credit-rating outlook change | FY2027 |
| Trade-remedy decisions on phenol/acetone/intermediates | Event-driven |
| Governance: remuneration and board independence developments | 2027 AGM |
Analyst verdict
Deepak Nitrite sits at the most consequential juncture in its 56-year history. The company that earned INR 1,067 Cr in FY2022 saw profits roughly halve by FY2026 as two forces converged: normalization of abnormal phenol spreads and a structural assault on its legacy Advanced Intermediates business from Chinese overcapacity. Q1 FY2027 then delivered the best quarter on record, proving that the Phenolics platform, once integrated and running full, can generate margins in the mid-20s at the EBIT level. The central analytical question is whether that quarter marks a new earnings floor or a cyclical peak.
The evidence supports a more cautious middle reading. Integration benefits — captive nitric acid, contracted pipeline propylene, and new acetone derivatives — are durable and should lift the through-cycle margin above the FY2025–FY2026 trough of 13–14% EBITDA. But Phenolics remains a spread business, AI is still earning single-digit margins, and the group is entering a heavy-investment phase in which debt could rise roughly five- to six-fold before the polycarbonate and BPA assets contribute, now not before H2 FY2028–FY2029.
The strategic logic of a cumene-to-polycarbonate chain in an import-dependent Indian market is sound, and DNL's Dahej execution record lends credibility. Yet the size of the bet relative to current cash generation, the slippage already visible in PC timelines, global PC/BPA overcapacity, and governance signals (combined CMD role, family executive concentration, AGM dissent) justify a risk premium.
At ~26x trailing earnings and ~16x EV/EBITDA after a ~38% five-year share-price decline, the market is pricing partial recovery, not the full integration thesis. We would characterize the stock as a long-duration execution story with near-term earnings momentum.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Since / tenure | Background |
|---|---|---|---|
Deepak C. Mehta | Chairman & Managing Director | Long-tenured promoter-CMD (several decades) | Promoter; holds 16.56% directly (June 2026). Also associated with Deepak Fertilisers & Petrochemicals group entities that appear in promoter group |
Maulik D. Mehta | Deputy Managing Director (from 9 May 2026, five-year term); previously Executive Director & CEO (since June 2020); also ED & CEO of Deepak Chem Tech | ~16+ years in group | BBA (University of Liverpool); Master's in Industrial & Organisational Psychology (Columbia University); Owner/President Management programme (Harvard Business School). Leads major project execution and ESG agenda |
Meghav D. Mehta | Deputy Managing Director (from 9 May 2026, five-year term) | Previously non-executive director; director of DCTL | Signed Gujarat government MoU on behalf of DCTL |
Sanjay Upadhyay | Director (Finance) & Group CFO | Re-appointed for five years from 1 August 2026 | Long-standing group CFO |
Anant Pande | Executive Director & Chief Marketing Officer | Three years from 5 August 2026 | Appointed at 55th AGM |
Lohit Shringi | CEO — Advanced Intermediates Business | Appointed 4 August 2026 (KMP/senior management, not board) | — |
Arvind Bajpai | Company Secretary | — | Signs exchange communications |
Governance Overview
| Attribute | Detail |
|---|---|
Board size | 13 directors |
Executive directors | 5 (Deepak C. Mehta, Maulik Mehta, Meghav Mehta, Sanjay Upadhyay, Anant Pande — composition inferred from appointments; verify against filing) |
Recent exits | Dileep Choksi (independent) ceased 7 August 2026 on completion of second term |
Chair/CEO separation | No — the Chairman is also Managing Director, and three executive seats are held by the promoter family |
Major Shareholders
| Holder category | % |
|---|---|
Promoter & promoter group | 49.34 |
Mutual funds | 11.45 |
Insurance companies | ~10.3 (April 2026 data) |
Total DII | 23.8 |
FII/FPI (154 FIIs) | 6.24 |
Retail & others | ~20.6 |
Promoter pledge | 0 |
Major Shareholders by Holder
| Holder | Stake (%) | As of |
|---|---|---|
Deepak Chimanlal Mehta (promoter) | 16.56 | Jun 2026 |
Deepak Novochem Technologies Ltd (promoter entity) | 3.41 | 2025–26 |
Kotak Mahindra Mutual Fund (all schemes) | 3.36 | Jun 2026 |
Franklin Templeton Mutual Fund | 2.67 | Jun 2026 |
Nippon India Mutual Fund | 1.86 | Jun 2026 |
ICICI Prudential Mutual Fund | 1.29 | Jun 2026 |
Sundaram Mutual Fund | 0.78 | Jun 2026 |
Investor Education & Protection Fund | 0.50 | 2,026 |
Canara Robeco Mutual Fund | 0.38 | Jun 2026 |
Mirae Asset Mutual Fund | 0.30 | Jun 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Overlap | Relative positioning |
|---|---|---|---|---|
Phenolics | Hindustan Organic Chemicals (HOCL) | India | Phenol/acetone (Kochi) | Small, state-owned; DNL is the dominant domestic producer |
Phenolics | Imports from Korea, Taiwan, Thailand, China, Singapore, Saudi Arabia (e.g., Kumho P&B, PTT Global Chemical, Mitsui Chemicals, INEOS Phenol, Chinese producers) | Global | Phenol, acetone | — |
Phenolics (IPA/solvents) | Deepak Fertilisers & Petrochemicals (IPA), Chemplast and others | India | IPA | Promoter-group-related entity also produces IPA (verify overlap) |
Phenolics derivatives (MIBK/MIBC) | — | Global | MIBK/MIBC | New entrant domestically |
Advanced Intermediates | Aarti Industries | India | Nitro-chlorobenzenes, nitro-aromatics, agro/pharma intermediates | Larger, more export-oriented |
Advanced Intermediates | Atul Ltd | India | Aromatics, intermediates, crop protection | Diversified specialty peer |
Advanced Intermediates | Vinati Organics | India | Specialty intermediates (IBB, ATBS) | Higher-margin niche player |
Advanced Intermediates | Navin Fluorine | India | Fluorinated intermediates | Competes with DCTL's fluorination ambitions |
Advanced Intermediates | Clean Science & Technology | India | Performance chemicals | High-margin niche |
Advanced Intermediates | Laxmi Organic, Sudarshan Chemical, Bodal Chemicals, Meghmani | India | Acetyls, pigments, dyes intermediates | Partial overlaps |
Advanced Intermediates | Chinese nitration/amine producers | China | Xylidines, nitro-toluenes, sodium nitrite, OBA | Primary source of FY24–FY26 price pressure |
Advanced Intermediates (OBA) | Global OBA producers (e.g., Archroma, Chinese producers) | Global | OBA/DASDA | — |
Advanced Materials (PC/BPA) | Covestro, SABIC, Lotte Chemical, Mitsubishi Chemical, Chinese PC producers; domestic: none at scale | Global | PC resin, BPA | DNL would be first large Indian PC resin producer |
Peer Comparison FY2026
| Metric | Deepak Nitrite | Aarti Industries | Atul Ltd | Navin Fluorine | Vinati Organics |
|---|---|---|---|---|---|
Revenue FY26 (INR Cr) | 7,887 | 9,018 | 6,274 | 3,379 | 2,227 |
Revenue growth FY26 (%) | -5 | 12 | — | 41 | 0 |
PAT FY26 (INR Cr) | 551 | 419 | 689 | 664 | 444 |
Net margin FY26 (%) | 7.0 | 4.6 | 11.0 | 19.6 | 19.9 |
EBITDA FY26 (INR Cr) | 1,041 | 1,172 | — | — | — |



